|
Synonyms: CDP 6038 | CDP-6038 | CDP6038
Compound class:
Antibody
Comment: Olokizumab (CDP 6038) is a clinical stage anti-IL-6 monoclonal antibody [3], that was designed for potential to treat autoimmune diseases. The antibody blocks assembly of the hexameric IL-6/IL-6 α-receptor/gp130 (IL6ST) complex that is required for signal transduction.
|
| References |
|
1. Genovese MC, Durez P, Fleischmann R, Tanaka Y, Furst D, Yamanaka H, Korneva E, Vasyutin I, Takeuchi T. (2021)
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. Eur J Rheumatol, 8 (3): 120-129. [PMID:34101570] |
|
2. Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, Jose J, Oliver R. (2014)
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev, 3 (5): 388-95. [PMID:27129012] |
|
3. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014)
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs, 6 (3): 774-82. [PMID:24670876] |
|
4. (2018)
Erratum. Mod Rheumatol, 28 (5): 911-912. [PMID:29869893] |
